As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: May 30, 2013
by Business Standard:
A blood test that detects distinct metabolic signatures in blood plasma may diagnose Alzheimer’s years before patients begin showing cognitive decline, scientists believe.
Researchers at Mayo Clinic analysed cerebrospinal fluid and plasma samples from 45 people in the Mayo Clinic Study on Aging and Mayo Clinic Alzheimer’s Disease Center (15 with no cognitive decline, 15 with mild cognitive impairment and 15 with Alzheimer’s disease).
They detected significant changes in the cerebrospinal fluid and plasma in those with cognitive decline and Alzheimer’s. Most important, changes in plasma accurately reflected changes in the cerebrospinal fluid, validating blood as a reliable source for the biomarker development.
The team used a relatively new technique called metabolomics, which measures the chemical fingerprints of metabolic pathways in the cell – sugars, lipids, nucleotides, amino acids and fatty acids – to detect the changes.
Metabolomics assesses what is happening in the body at a given time and at a fine level of detail, giving scientists insight into the cellular processes that underlie a disease.
In this case, the metabolomic profiles showed changes in metabolites related to mitochondrial function and energy metabolism, further confirming that altered mitochondrial energetics is at the root of the disease process.
The researchers hope that identified changes in the metabolic pathways could lead to the panel of biomarkers, which can eventually be used on a larger scale for early diagnosis, monitoring of Alzheimer’s progression, and evaluating therapeutic approaches, said co-author Eugenia Trushina, a Mayo Clinic pharmacologist.
“We want to use these biomarkers to diagnose the Alzheimer’s disease before symptoms appear – which can be decades before people start exhibiting memory loss,” Trushina said.
The study was published in the journal PLOS ONE.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.